Samsung Biologics expands into the United States: Acquisition of Rockville biologics manufacturing facility

Entry to the U.S.: New Addition to Samsung Biologics

The newly acquired Rockville site includes two drug manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical-stage and commercial pharmaceutical production. The $353M acquisition marks Samsung Biologics' first entry into the United States and a major step in Samsung's broader, long-term investment plan in U.S. manufacturing and innovation.

The Rockville facility at a glance:

• First U.S. manufacturing site for Samsung Biologics
• 60,000 liters of added drug substance capacity
• 845,000 liters of total manufacturing capacity across all global campuses"
• 500+ skilled employees retained in Rockville, Maryland

Local Presence, Global Impact

Located in one of the United States' leading biotechnology hubs, the Rockville facility will retain more than 500 skilled employees, strengthening Maryland's life sciences workforce and expanding Samsung Biologics' ability to support clients in the U.S. and across the world.